您的位置: 百康网 > 期刊 > 神经病学与精神病学 > 《印度神经学医学期刊》 > 2006年4月第2期 > 正文
Is myasthenia gravis more benign in the Indian population?
 本页关键词:myasthenia
2007-6-11 11:42:32

  1 Departments of Neurology, Little Flower Hospital and Research Centre, Angamaly, Kerala, India
  2 Departments of Ophthalmology, Little Flower Hospital and Research Centre, Angamaly, Kerala, India

  The paper authored by Panda et al stimulated our curiosity.[1] We were especially intrigued by two patients (No: 2 and 5) who had ocular myasthenia with thymoma and remained in MGFA Class I for five and three years respectively before going into crisis. This goes against two grains of conventional wisdom that a) ocular myasthenia tends usually not to generalize after three years and b) the course of patients with thymoma is aggressive with frequent crises. There is no inviolable tenet in medicine and the first aphorism derives from a study of natural history which found generalized myasthenia developing in less than 6% if weakness remained confined to ocular muscles in the first three years.[2] The serological status of these patients and the nature and grade of thymoma would be of interest. We would like to know whether the institutional protocol included pre-thymectomy plasmapheresis.

  The paper suffers a few flaws that plague retrospective studies. Since the point of entry was through ward admission, patients with Classes I and IIa who may conceivably have been treated as outpatients in the Neurology or Ophthalmology departments would be excluded. Hence the proportion of myasthenics developing crisis could well be even lower than the 9.69% computed. This is significantly less than expected but corresponds with the conclusions of a study of ocular myasthenia from our institution.[3] No myasthenic crisis was encountered in 48 patients who had presented in MGFA Class I. The follow up period was over five years in 5 and 3 years in 20 patients. Despite the logical hypothesis advanced by the authors that infections and drug default could trigger frequent crises in developing countries our impression is that ocular onset myasthenia behaves less aggressively in our subjects. The alternative explanation would be that the incidence of crisis is overstated in most neurological series because of the greater proportion of severely affected patients.

  Bulbar involvement may hasten respiratory compromise because of pooling of secretions. However, bulbar involvement is almost universal during myasthenic crisis and often heralds crisis rather than instigates it. Only 2 of the 11 patients were reported to have bulbar involvement when previously classified and it would be incorrect to infer from this data that bulbar presentation confers higher risk of crisis.

  Minor criticisms apart, the investigators deserve congratulation and more needs to be studied about this disease that exhibits ethnically diverse behavior.

  References
  1. Panda S, Goyal V, Behari M, Singh S, Srivastava T. Myasthenic crisis: A retrospective study. Neurol India 2004;52:453-6.

  2. Grob D, Arsura E, Brunner N, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci 1987;505:472-99.

  3. Gopinath D. Ocular Myasthenia - A Clinical Study. DNB Ophthalmol Thesis 2004.



查询更多myasthenia相关信息在本站>>

  

《印度神经学医学期刊》2006年4月第54卷第2期 

评论】【打印】【 】【关闭
相关文章
Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy
Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment
Strabismus surgery in the management of diplopia caused by myasthenia gravis
Dysphagia as the sole manifestation of myasthenia gravis
The features of myasthenia gravis with autoantibodies to MuSK
Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis
Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)
Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymoma
Thymoma is associated with relapse of symptoms after transsternal thymectomy for myasthenia gravis
Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis